Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
AbbVie Signs Deals With Infinity …
by Ann M. Thayer
September 8, 2014
| A version of this story appeared in
Volume 92, Issue 36
Infinity Pharmaceuticals and AbbVie will develop and commercialize Infinity’s cancer drug candidate duvelisib. The clinical-stage drug is a small-molecule inhibitor of phosphoinositide-3-kinase (PI3K ) delta and gamma that has shown activity across a range of hematologic cancers. AbbVie will pay $275 million up front and up to $530 million more if milestones are met. As part of its drug development strategy, Infinity also is looking to combine duvelisib with other cancer therapies. It just signed a deal to evaluate duvelisib in combination with Roche’s anti-CD20 therapy Gazyva (obinutuzumab).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X